YCANTH (VP-102)
Molluscum Contagiosum
Key Facts
About Verrica Pharmaceuticals
Verrica Pharmaceuticals is a US-based, publicly traded company dedicated to transforming the treatment landscape for viral skin diseases and dermatologic oncology. Its core achievement is the 2023 FDA approval and commercialization of YCANTH for molluscum contagiosum, a significant milestone addressing a large pediatric population. The company's strategy involves expanding YCANTH's label into common warts and developing VP-315, an oncolytic peptide licensed from Lytix Biopharma, for non-surgical treatment of basal cell carcinoma. Verrica is positioning itself as a leader in medical dermatology with a focus on accessible, in-office procedures.
View full company profileAbout Verrica Pharmaceuticals
Verrica Pharmaceuticals is a US-based, publicly traded company dedicated to transforming the treatment landscape for viral skin diseases and dermatologic oncology. Its core achievement is the 2023 FDA approval and commercialization of YCANTH for molluscum contagiosum, a significant milestone addressing a large pediatric population. The company's strategy involves expanding YCANTH's label into common warts and developing VP-315, an oncolytic peptide licensed from Lytix Biopharma, for non-surgical treatment of basal cell carcinoma. Verrica is positioning itself as a leader in medical dermatology with a focus on accessible, in-office procedures.
View full company profileAbout Verrica Pharmaceuticals
Verrica Pharmaceuticals is a US-based, publicly traded company dedicated to transforming the treatment landscape for viral skin diseases and dermatologic oncology. Its core achievement is the 2023 FDA approval and commercialization of YCANTH for molluscum contagiosum, a significant milestone addressing a large pediatric population. The company's strategy involves expanding YCANTH's label into common warts and developing VP-315, an oncolytic peptide licensed from Lytix Biopharma, for non-surgical treatment of basal cell carcinoma. Verrica is positioning itself as a leader in medical dermatology with a focus on accessible, in-office procedures.
View full company profileTherapeutic Areas
Other Molluscum Contagiosum Drugs
| Drug | Company | Phase |
|---|---|---|
| Exploratory Asset | Veradermics | Exploratory/Pre-clinical |